Ex 99.1

1 | NASDAQ: SLP 16 th Annual Needham Technology & Media Conference Shawn O’Connor, CEO May 20, 2021

2 | NASDAQ: SLP With the exception of historical information, the matters discussed in this presentation are forward - looking statements that involve a number of risks and uncertainties . The actual results of the Company could differ significantly from those statements . Factors that could cause or contribute to such differences include but are not limited to : continuing demand for the Company’s products, competitive factors, the Company’s ability to finance future growth, the Company’s ability to produce and market new products in a timely fashion, the Company’s ability to continue to attract and retain skilled personnel, and the Company’s ability to sustain or improve current levels of productivity . Further information on the Company’s risk factors is contained in the Company’s quarterly and annual reports and filed with the Securities and Exchange Commission . Safe Harbor Statement

3 | NASDAQ: SLP Our mission is to create value for our customers by accelerating and reducing the costs of R&D through innovative science - based software and consulting solutions that optimize treatment options and improve patient lives . Mission

4 | NASDAQ: SLP □ Industry - leading provider of modeling and simulation solutions used by major pharmaceutical, biotech, chemical, consumer goods companies and regulatory agencies worldwide □ Innovative software and services to improve drug development from discovery to regulatory approval with supportive guidance from the FDA and ability to lower cost and time to market with a higher likelihood of success □ Solutions bridge machine learning and include pharmacokinetic - pharmacodynamic ( PKPD ), quantitative systems pharmacology & toxicology ( QSP/QST ), and physiologically based pharmacokinetic ( PBPK ), Physiologically - Based Biopharmaceutics ( PBBM ) Modeling □ 10+ year track record of consistent revenue and profitability growth and successful M&A strategy Company Overview

5 | NASDAQ: SLP Our solutions allow customers to model and predict results of chemical and biological tests required in the R&D process to improve success rates at multiple points in the process: – Computational AI models help scientists streamline and improve their processes – Machine learning improves the models with ever - growing data sets – Better informed clinical trial design and analyze clinical results – Identify potential safety liabilities earlier, avoiding costly clinical failures – Optimize efficacy and minimize toxicity by efficiently identifying dosing regimens Our Value Proposition Avg. cost of $1.4B and 10+ years to bring a drug to market 1,2 We’ve helped bring 40+ drugs to market and informed multiple development programs

6 | NASDAQ: SLP We Improve Drug Discovery and Development

7 | NASDAQ: SLP PBPK Software Solutions and AI Data Mining Simulating IV, oral, oral cavity, ocular, inhalation, skin and IM absorption, PBPK, PBBM, PD modeling and drug - drug interactions QSAR modeling enabling rapid prediction of 140+ ADMET properties Used for lead generation and optimization Mechanistic simulation engine for the in vitro dissolution predictions to accelerate and optimize drug formulation Predict how fast a drug candidate will pass across the important physiological membrane barriers (GI, BBB) Chemical sketching tool with ADMET property predictions in connection with ADMET Predictor GastroPlus ® ADMET Predictor ® DDDPlus Œ MembranePlus Œ MedChem Designer Œ

8 | NASDAQ: SLP PKPD Software Solutions Population PKPD Model to support dose regimen, risk exposure, clinical trial protocol design and analysis, drug label specifications and regulatory submission Cloud - based data management application Datxplore PKanalix Mlxplore Monolix Simulx Exploration and visualization of data Non - compartmental and compartmental analysis Exploration and visualization of complex models Non - linear mixed effects (NME) modeling engine Clinical trial pharmacometrics simulations Monolix Suite ® KIWI Œ

9 | NASDAQ: SLP QSP/QST Software Solutions Determine potential drug - induced liver injury hazard posed by individual drug candidates to support clinical trial optimization Assess the potential for drug - induced kidney injury of drug candidates to support clinical trial optimization and clinical trial decision making NASH model to predict efficacy for treatment modalities to support clinical trial optimization and clinical trial decision making IPFsym (Idiopathic pulmonary fibrosis) RADAsym (Acute radiation exposure) RENAsym Œ DILIsym Œ RADAsym Œ NAFLDsym Œ IPFsym Œ

10 | NASDAQ: SLP • 70+ scientific PhD experts provide insightful solutions to improve the productivity of science - based drug development • Focusing on lead selection, pharmacology, ADMET and DMPK, dose regimen, efficacy and safety • Capabilities include: – Population PKPD data assembly, modeling, simulation, analysis and regulatory submission – PBPK modeling and simulation – Liver and kidney safety modeling and analysis – QSP/QST modeling support and analysis – AI drug candidate prioritization – Global regulatory strategies – Regulatory and scientific writing Services Solutions

11 | NASDAQ: SLP Janssen Case Study: Accelerating Regulatory Interactions Virtual crossover trials to establish drug product specification after manufacturing changes • Janssen changed the manufacturing process to improve efficiencies with scale - up techniques post approval • FDA requested clinical study to confirm bioequivalence • Built and validated the baseline model in GastroPlus® using existing clinical data from previously approved lots • Assessed impact of formulation changes; defined drug product specifications • Performed virtual trial simulations in different populations to confirm bioequivalence • FDA accepted the GastroPlus® modeling results, clinical study request was waived

12 | NASDAQ: SLP In Silico Methods Improve the Probability of Phase 3 Success Client Case Study: Strategic Use of Modeling & Simulation • Client with novel antibody for prophylactic use in competitive migraine market had Phase 3 development plan with predicted probability of success of <15% • Iteratively developed model throughout Phase 1 & Phase 2 • I mplemented model - based clinical trial simulation strategy to improve Phase 3 design • Phase 3 trials demonstrated safety and efficacy in preventing migraine • Months of development time and millions of dollars saved by avoiding failed Phase 3 trials, also reduced time to approval and market • Reduced unnecessary burden on patients by evaluating multiple alternatives in silico before running trials

13 | NASDAQ: SLP Growth Drivers Increasing acceptance of modeling and simulation by FDA and drug industry High customer satisfaction with ~95% software contract renewal rate (by fees) Recently improved and expanded sales infrastructure Increasing opportunities for product and service cross - selling Synergistic acquisitions Steadily increasing industry R&D spend 19%+ Revenue CAGR

14 | NASDAQ: SLP $14.9 $17.0 $18.5 $21.6 $14.0 $9.2 $12.7 $15.5 $20.0 $9.8 FY17 FY18 FY19 FY20 FY21 YTD Software Services Consistent Revenue Growth FY21 YTD (through Q2) (in millions) $24.1 $29.7 $34.0 $23.8 $41.6

15 | NASDAQ: SLP Software and Services Performance FY21 YTD (through Q2) Software Products % of Software Revenues 56% 19% 17% 8% GastroPlus Monolix Suite ADMET Predictor Other Software 19% 29% 52% PBPK QSP/ QST PKPD Services Offerings % of Services Revenues 59% of Total Revenue 41% of Total Revenue

16 | NASDAQ: SLP Global Customer Base 66% Americas 23% EMEA 11% Asia Pacific Revenue by Region FY21 YTD (through Q2)

17 | NASDAQ: SLP • Expand product offerings through opportunistic acquisitions – Fill gaps in the current product offerings – Focus on immediately or near - term accretive opportunities – Fragmented industry amenable to consolidation • Further expand global sales reach – Increase sales effort to drive new customer growth in U.S., Europe and Asia – Expand client base in the small and mid - sized biotechnology space – Focus on cross - selling efforts to increase average revenue per customer • Increase R&D investment to enhance existing models and develop new tools to broaden product offerings Strategic Opportunities for Expansion and Growth

18 | NASDAQ: SLP • Total Revenue Growth – YTD performance: 21% y/y growth – Full - year guidance range: 15 - 20% y/y organic growth plus 3 - 5% from Lixoft • Software Revenue Growth – YTD performance: 40% y/y growth – Full - year guidance range: 20 - 25% y/y growth • Services Revenue Growth – YTD performance: 1% y/y growth – Full - year guidance range: 25 - 30% y/y growth • YTD Profitability – Gross margin was 78%, up from 73% prior fiscal year – Net income increased 35% y/y to $5.7 million – Diluted earnings per share increased 17% y/y to $0.27 • M&A Efforts – Continuing to explore opportunities and acquisitions that would be incremental to revenue growth targets above FY21 Q2 YTD Performance & FY21 Full Year Guidance

19 | NASDAQ: SLP x Leading provider of innovative modeling and simulation software and consulting services focused on pharmaceutical and biotechnology companies » Solutions from early discovery through regulatory approval x Pure play in the in silico drug discovery space x Growing acceptance of technology by regulators and industry with supportive guidance issued by the FDA x Products have the potential to reduce drug development costs and time while improving success rates x Steady growth in pharmaceutical industry R&D expenditures provides expanding target market » ~$170B in 2020 growing around 3% per year 3 x 10+ year track record of consistent revenue and profitability growth » Recent revenue CAGR of 20%+ Investment Highlights

20 | NASDAQ: SLP Financial Summary and Selected Financial Information Nasdaq Global Select Market SLP Q2 Cash and short - term investments $118M Q2 Borrowed Debt Outstanding $0 Market Capitalization (a/o 5/12/21) $1.1B Q2 Fully Diluted Shares Outstanding 20.8M 30 - Day Avg. Daily Trading Volume (a/o 5/12/21) ~204K

21 | NASDAQ: SLP Covering Analysts Bank Analyst Craig - Hallum Matt G. Hewitt Oppenheimer & Co. Francois Brisebois Raymond James Dane Leone

22 | NASDAQ: SLP Q&A Questions & Answers Thank you!

23 | NASDAQ: SLP 1. J Health Econ . 2016 May;47:20 - 33. 2. Brochure: “Biopharmaceutical Research & Development: The Process Behind New Medicines” . PhRMA. 3. EvaluatePharma® World Preview 2017, Outlook to 2022, 10th Edition, June 2017, p. 19. References